Everything you need to know to stay updated on the financial market. Information, trend and graph in real time on the stock exchange quotations of the major stocks on world stock exchanges.
ISIN code: FR0000120578
Sector: Healthcare technology
Industry: Pharmaceuticals: major
Le actions of Sanofi are listed on the Euronext market with the ticker SAN and on the Milan Stock Exchange with the ticker SANF.
Look at the history of the quotation of the share on the Milan index
Company Description
Sanofi is a French company operating in the pharmaceutical sector. The Sanofi group was created in 2004 by the merger of Aventis e Sanofi-Synthelabo.
Its head office is in Paris.
Sanofi is present in more than 100 countries. It has over 100.000 employees worldwide. In Italy there are about 2000.
It has subsidiaries all over the world and is one of the world's largest pharmaceutical groups. It is also the leading pharmaceutical group in developing countries.
Sanofi's main operating areas are: self-medication and over-the-counter medicines, diabetes and cardiovascular, immunology, multiple sclerosis, rare blood diseases, oncology and vaccines.
In 2019, the company's global turnover was 37.631 billion euros with a net profit of 2.8 billion. In Italy, it had a turnover of approximately 1,4 billion euros.
In the healthcare sector, Sanofi ranks third in the world by revenue, but only eleventh by market capitalization.
Sanofi generates 72,6% of its sales outside Europe.
It is listed in theEuronext index (main pan-European financial market and stock exchange in the Eurozone).
I major shareholders I'm:
- L'Oréal SA 9,5%
- Norges Bank Investment Management 2,24%
- The Vanguard Group, Inc. 2,16%
- Plan d'Epargne Entreprise Sanofi Synthelabo 1,80%
- Dodge & Cox 1,61%
- Fidelity Management & Research Co. LLC 1,33%
- Amundi Asset Management SA (Investment Management) 1,09%
Sanofi shares are currently trading at around 88 euros.
The tagline is «Empowering Life».
Economic and financial analysis of the company
Sanofi was born in 1973 with the acquisition of the pharmaceutical group labaz by the oil company Elf Aquitaine. Their first product was a drug for the prevention of cardiovascular events.
Sanofi has four research and development hubs around the world, for which it invested approximately 5,5 billion euros, equal to 15,6% of turnover in 2017.
The company, since 2016, organizes its activities in five business units: General Medicines (mature products), Diabetes & Cardiovascular, Consumer Healthcare (self-medication), Sanofi Genzyme (rare diseases, multiple sclerosis, oncology and immunology) and Sanofi Pasteur (vaccines).
In Italy, Sanofi is present with the headquarters of Milano and with offices in Modena (Sanofi Genzyme Headquarters) ea Roma (institutional and Sanofi Pasteur headquarters). In addition, it owns four industrial plants in Origgio (Va), Anagni (FR), Scoppito (AQ) and Brindisi.
The first acquisitions began in 1983 with the Ela Medical followed in 1985 by Rousselot.
In 1989 Sanofi expanded into the eastern market by acquiring the Hungarian laboratory Chinoin.
In 1994 the group made its first significant appearance in the United States with the acquisition of Sterling Winthrop Pharmaceuticals. This acquisition transforms Sanofi into a major global pharmaceutical group.
In 1999 Sanofi merged with Synthelabo and Sanofi-Synthélabo was born.
In 2004, Sanofi-Synthélabo acquires Aventis for 55 billion; is born Sanofi-Aventis. This merger makes the company the third largest pharmaceutical group in the world.
In September 2008, he bought the Czech company for 1,8 billion euros Zentiva, expanding its presence in Eastern European markets.
In 2009, Medley Pharma, the third-largest pharmaceutical company in Brazil and one of the leading generics companies in that country, is being bought by Sanofi-Aventis for approximately $635 million. Also in 2009, it acquired the Indian vaccine manufacturer Shantha Biotechnics for 784 million dollars.
In 2010, he bought the US health products company Chattem Inc. for about 1,9 billion dollars, Nepentes Pharma for 130 million dollars and BMP Sunstone Corporation for 520,6 million dollars.
In March 2011, seven years after the merger, the Sanofi-Aventis group changed its name to Sanofi. The reason the company gave for the change was to make its name easier to pronounce in countries like China.
Also in 2011, it acquires Genzyme Corporation for approximately $20,1 billion. This Cambridge, Massachusetts-based biotechnology company specializes in the treatment of kidney disease, endocrinology, oncology, and biosurgery.
In July 2015 he bought for 300 million dollars from AstraZeneca, Caprelsa, a drug for a rare form of cancer, and signs a cancer research partnership with Regeneron Pharmaceuticals for about two billion dollars.
In August 2015, Sanofi announces its cooperation with Google Life Sciences, a department of Google which brings together all activities related to health, with the aim of improving clinical outcomes in diabetes.
In July 2017, Sanofi buys Protein Sciences, a company specializing in a recombinant flu vaccine. for 650 million dollars.
In January 2018, Sanofi completes the acquisition of bioverativ, a US company specializing in hemophilia, for 11,6 billion dollars, Ablynx for 3,9 billion euros and sells Zentiva to the investment fund in April Advent International for 1,92 billion euros.
In December 2019, Sanofi announces the acquisition of Synthorx, American Oncology Society, for $2,5 billion.
A change in strategy is announced that ends research on diabetes and cardiovascular disease; this change of strategy also leads to a cut in jobs. The company's focus will be primarily on vaccine research.
To recover resources Sanofi sells its 20% stake in Regeneron for almost 12 billion dollars.
In June 2020, Sanofi acquires a 7% stake in Translate Bio, as well as an exclusive use of its mRNA tools, for $2 billion, expanding an existing collaboration for COVID-19 treatments.
During the summer of 2020, Sanofi announces theacquisition of the American Principia Biopharma, a company specializing in the treatment of autoimmune diseases, for an amount estimated at $3,68 billion.
In 2020, Regeneron announces plans to buy back approximately $5 billion of its shares, held directly by Sanofi.
In November 2020 Sanofi announces the purchase of Kiadis Pharma for €308 million.
In January 2021, complete the acquisition of Kymab, immunotherapy company, for $1,5 billion.
At the beginning of February 2021, the group announced a tripling of its annual profit to 11 billion euros, including 7 billion in capital gains following the sale of Regeneron shares.
In April 2021, Sanofi acquired the American company Tidal Therapeutics for $160 million with the hopes of improving its expertise in immuno-oncology and inflammatory diseases.
In June 2021, Sanofi announces sale of set of 16 advisory drug brands to investment fund Stada for an estimated amount of between 120 and 140 million euros.